Compare Biogen Inc (BIIB) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs General Dynamics Corporation — how do they compare? Biogen Inc trades at $197.8 (market cap $28.34B), while General Dynamics Corporation trades at $366.5 (market cap $99.92B). The key difference: General Dynamics Corporation is far larger — about 3.5× Biogen Inc's market cap, and General Dynamics Corporation pays a 1.72% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | GD | |
|---|---|---|
Market Cap | $28.34B | $99.92B |
Sector | Health | Industrials |
52-Week High | $216.63 | $376.88 |
52-Week Low | $122.68 | $297.05 |
Enterprise Value | $30.62B | $106.10B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
General Dynamics (GD) trades at $372.78, down 0.61% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.10 versus $3.67 expected, and maintains solid fundamentals including 8.07% net income margin and 17.97% ROE. Revenue growth continues, reaching $52.55 billion in 2025, with a robust backlog of $130.8 billion highlighting strong demand in naval and defense sectors.
Outlook remains positive driven by defense spending tailwinds and submarine contract momentum, though valuation multiples like P/E of 23.46 suggest limited upside near-term. Risks include execution on large contracts and geopolitical volatility. Analyst consensus is bullish with a $395.83 price target, indicating ~6% potential appreciation from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
